Asked about the drivers for the steep second-half margin ramp (organic growth vs. cost initiatives) and confidence in AI demand, as well as Bruker's position in spatial biology amidst new instrumentation launches.

Gerald Herman attributed margin ramp primarily to cost-saving actions and sequential revenue improvement. Frank Laukien expressed confidence in durable AI trends (semi metrology, SciY) and asserted Bruker's leadership in spatial biology with comprehensive multi-omic and high-plex proteomics capabilities, noting their offerings are already delivering. “Our operating margin performance is very strongly driven by our cost-saving actions, and you've already heard me describe those in my prepared remarks. We're expecting 300 to 350 basis points of organic improvement.”

Inquired if the $40 million semi push-out from last quarter was recaptured in Q1 and about the outlook for U.S. academic demand.

Frank Laukien stated only "some" of the semi push-out was recaptured in Q1. For U.S. academic, he noted demand seems to have "bottomed or stabilized" and expressed "somewhat optimistic" that funding disbursements will pick up in Q2/Q3, leading to good orders in H2, but this is not built into current guidance. “I'm somewhat optimistic that there will be a fair amount of funding between now and the end of the government fiscal year at the end of September and perhaps that will relate to good Q2 or Q3 orders.”

Asked if Q1 saw pull-forward from Q2 given Q2's favorable comparison, and if Q2 is still expected to be the highest organic growth quarter. Also, whether current guidance fully accounts for potential increases in freight/input costs.

Frank Laukien confirmed Q2 is expected to be the highest organic growth quarter, with minimal pull-forward into Q1 ($8M-$10M). Gerald Herman confirmed the guidance fully captures variability from energy/input costs, with cost savings providing a cushion. “mathematically, yes, that looks to be correct that we -- as we see it right now, the cadence is indeed that the organic revenue growth in Q2 would probably be the highest of the year.”

BRKR

Bruker (BRKR) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Health Care· May 6, 2026

Source: earnings call transcript

Executive summary

Bruker Corporation Q1 FY26 — Strong Bookings and Cost Savings Drive Q1 Beat

Bruker delivered Q1 FY26 results ahead of expectations, driven by strong BSI bookings momentum and effective cost-saving actions, despite a 4.4% organic revenue decline and significant margin headwinds. The company reconfirmed its full-year guidance, anticipating a return to organic revenue growth in Q2 and continued margin expansion, supported by AI-driven businesses and a stabilizing BEST segment. Management remains focused on cost control and innovation to navigate a dynamic macro environment.

Highlights

Q1 FY26 financial performance came in "well ahead of expectations" despite macro headwinds.
BSI segment organic bookings grew in the "high single digits" in Q1 FY26, with book-to-bill "comfortably above 1.0" for the third consecutive quarter.
AI-driven semiconductor metrology, SciY software, and European Middle East security detection businesses all saw organic bookings growth of "greater than 20%" in Q1 FY26.
BEST segment secured "$80 million" of multiyear orders for Fusion Technologies and "$600 million" of multiyear orders for high-performance superconductors.
Annualized cost savings are now tracking around "$140 million", exceeding the prior target of "$100 million to $120 million".

Concerns

Organic revenue declined "4.4%" year-over-year in Q1 FY26.
Non-GAAP gross margin decreased "130 basis points" to "50%" in Q1 FY26.
Non-GAAP operating margin decreased "250 basis points" to "10.2%" in Q1 FY26.
Q1 FY26 diluted non-GAAP EPS was "$0.31", down from "$0.47" in Q1 FY25.
China revenue declined "greater than 20%" organically year-over-year.
Continued pressure from U.S. academic demand, tariffs, and currency headwinds.

Guidance & targets

Category	Target	Timeline	Confidence
Full Year 2026 Reported Revenue	$3.57 billion to $3.60 billion high materiality	FY26	High
Full Year 2026 Organic Revenue Growth	1% to 2% high materiality	FY26	High
Full Year 2026 Non-GAAP Operating Margin Expansion	250 to 300 basis points high materiality	FY26	High
Full Year 2026 Organic Non-GAAP Operating Margin Expansion	300 to 350 basis points high materiality	FY26	High
Full Year 2026 Non-GAAP EPS	$2.10 to $2.15 high materiality	FY26	High
Q2 2026 Organic Revenue Growth	low to mid-single digits percentage medium materiality	Q2 · FY26	High
Q2 2026 Non-GAAP Operating Margin	meaningful year-over-year step-up medium materiality	Q2 · FY26	Medium
Q2 2026 Non-GAAP EPS	do better in the second quarter than we did sequentially on the first quarter of '26 medium materiality	Q2 · FY26	Medium

Segment performance

Segment	Revenue	YoY	QoQ	Margin
BSI (Bruker Scientific Instruments) Book-to-bill ratio comfortably above 1.0 for the third consecutive quarter. Expected to return to organic revenue growth in Q2. Organic bookings growth: high single digits	—	-5% organically	—	—
BEST (Bruker Energy & Supercon Technologies) Driven by superconducting wire business. Research instruments saw very strong orders. Orders from major MRI customers are for multiple years, stabilizing the segment for healthy single-digit organic growth. Multiyear orders for Fusion Technologies: $80 millionMultiyear orders for high-performance superconductors: $600 million (last 5 months)	—	3% organically	—	—
BioSpin Group Revenue growth in preclinical imaging systems, Sywise software, and services business were more than offset by weakness in NMR systems due to soft ACO performance in China and Europe. Headwind from absence of gigahertz class systems in Q1 FY26 vs. Q1 FY25.	$198 million	high single-digits percentage CER decline	—	—
CALID Group Growth led by molecular spectroscopy and security detection orders. Microbiology and infection diagnostics had solid revenue growth. Life science mass spectrometry saw M&A contributions offset by U.S. academic weakness, but orders growth was positive.	$316 million	mid-single-digit percentage CER growth	—	—
Nano Group Strong revenue growth in semi metrology was more than offset by weakness in academic and industrial markets. Strong orders across the group, including tools for X-ray industrial research, spatial biology, high-bandwidth memory, and advanced packaging metrology, all driven by AI.	$246 million	mid-single digits percentage CER decline	—	—

Product announcements

Product	Type	Timeline
NMR innovations (AI-driven protein NMR, Avance Neo console)	launch	2026
CosMx system enhancements	update	since last year
MyGenius Pro higher throughput system	launch	—

Deals & partnerships

Hitachi Introduction of MyGenius Pro system in Japan using Bruker's molecular diagnostic assay.

Hitachi is introducing Bruker's new MyGenius Pro higher throughput system in Japan, utilizing Bruker's molecular diagnostic assay for clinical microbiology.

Major MRI customers Multiyear orders for high-performance superconductors. $600 million multiple years

Bruker received approximately $600 million of multiyear orders for high-performance superconductors from all three major MRI OEM customers in the last 5 months (December through April).

Risks & headwinds

U.S. academic demand weakness Q1 FY26

continued to pressure our year-over-year results

Mitigation:Expects momentum once NIH funding environment improves; not banking on recovery for FY26 guidance.

Tariffs Q1 FY26, expected to ease in Q2 FY26

continued to pressure our year-over-year results

Mitigation:Expected to ease as company laps introduction of U.S. tariffs in Q2 FY25.

Currency exchange rates (FX) Q1 FY26, expected to ease in Q2 FY26

continued to pressure our year-over-year results

Mitigation:Expected to ease as company laps significant depreciation of U.S. dollar in Q2 FY25.

Lower volume and unfavorable mix Q1 FY26

350 basis points headwind to operating margin in Q1 FY26

Mitigation:Expects mix situation to improve through the rest of 2026.

Geopolitical environment Ongoing

dynamic macro... and geopolitical environment

Mitigation:Prudent to confirm prior FY26 guidance; cost-cutting initiatives provide cushion.

China revenue decline Q1 FY26

greater than 20% decline in Q1 FY26

Mitigation:Largely driven by weaker order demand in prior year; Q1 order performance was solid, showing improvement.

What to watch in Q2 FY26

U.S. Academic Funding Recovery

Q2 and Q3 FY26

Current bottomed or stabilized

Target pick up a little bit

Why it matters

Recovery in U.S. academic funding could provide upside to current guidance and drive future revenue.

I'm somewhat optimistic that there will be a fair amount of funding between now and the end of the government fiscal year at the end of September and perhaps that will relate to good Q2 or Q3 orders.

Find out whether BRKR delivers this. Inve re-checks your case every morning.

Q&A highlights

Inquired about the sustainability of strong OUS academic order growth and the aggregate contribution of niche markets like security detection and semi metrology to the portfolio.

Frank Laukien stated that while the Q1 OUS academic order rate was exceptionally high and likely not sustainable at that exact level, high single-digit growth is expected. He noted that niche growth drivers (semi metrology, SciY, security detection) collectively represent "well above 10%" of the portfolio, moving the needle.

“Yes, it's well above 10%, right? We haven't done that, but yes, a quick math would show that it's 10%, greater than 12%.”

asked by Michail Paraskevopoulos · answered by Frank Laukien

2 min read 7 chapters

Detailed narrative

Q1 Performance Ahead of Expectations

Bruker's Q1 FY26 financial performance exceeded internal expectations, despite facing significant macro and foreign exchange headwinds. The organic revenue decline of 4.4% year-over-year was better than originally anticipated, demonstrating strong execution by the teams. This outperformance provides improved visibility and confidence for the remainder of the fiscal year.

Strong Bookings Momentum

The BSI segment showed robust order trends, with organic bookings growing in the high single digits during Q1 FY26. This marks the third consecutive quarter where the BSI book-to-bill ratio was comfortably above 1.0, indicating sustained demand. Strength was observed in industrial research orders and encouraging double-digit academic order growth from outside the United States.

AI-Driven Growth Areas

Bruker is capitalizing on the AI megatrend through several specialized businesses. Its semiconductor metrology business, now exceeding $300 million in annual revenue, saw over 20% organic bookings growth, driven by demand for memory chips and advanced packaging. Similarly, the SciY scientific software business, with approximately $50 million in annual revenue, also achieved over 20% organic bookings growth by providing lab digitization and AI-ready data solutions.

BEST Segment Turnaround

The BEST segment experienced a significant turnaround, achieving 3% organic revenue growth net of intercompany eliminations. This was bolstered by substantial multiyear orders, including $80 million for Fusion Technologies and approximately $600 million for high-performance superconductors from major MRI customers over the last five months. These orders are expected to drive continued moderate organic growth for the segment.

Innovation and Product Launches

Bruker introduced impactful new products and solutions across its portfolio. Key innovations include AI-driven advancements in protein NMR, making it more accessible, and a new Avance Neo console. In spatial biology, the CosMx system was enhanced with whole mouse transcriptome and high-plex proteomics. Additionally, the new MyGenius Pro higher throughput system was launched for clinical microbiology and molecular diagnostics.

Cost-Saving Initiatives

The company's cost-out plan, referred to as the Bruker management process, is yielding substantial benefits. Annualized cost savings are now tracking at approximately $140 million, surpassing the initial target of $100 million to $120 million. The majority of these savings are expected to be reflected in the second half of FY26 and beyond, contributing significantly to margin expansion and EPS growth.

Geographic and End-Market Dynamics

Geographically, Americas and European revenues declined in the low single digits organically, while Asia Pacific saw a low double-digit decline, primarily due to a greater than 20% drop in China revenue. However, China orders showed solid improvement in Q1. From an end-market perspective, organic revenue growth in semi, biopharma, and hospital clinical markets partially offset double-digit declines in academic government research and industrial markets.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.